News

The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology1.   Viralym-M is an "off-the-shelf", 3rd party T-cell product

Under the agreement, Grid has acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor H (CFH) antibodies as a cancer therapy, and

Both the compounds were discovered through the research collaboration between Zealand and Boehringer Ingelheim. According to Zealand, the glucagon/GLP-1 agonist activates two key gut hormone receptors GLP-1 and

Ibrance is an oral inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), which triggers cellular progression. Patina is a randomized, open-label and phase 3 clinical trial, which will assess

This marks the second program Ovid has advanced into Phase 2 clinical development this year. Takeda and Ovid formed a global collaboration focused on the clinical development and

Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking,

Under the deal, the partnership will develop new stabilised non-immunogenic modified RNA therapies (mRNA) for respiratory diseases by using Ethris’ SNIM RNA technology. As per terms of the

Duzallo is a combination of 200mg of lesinurad and 300mg of allopurinol and has been approved by the regulator as a once-daily oral therapy for treating the condition

Ligand is also entitled to future milestones and royalties from this antibody. WuXi Biologics was previously contracted by its Chinese partner Harbin Gloria Pharmaceuticals to discover and develop